J&J pushes new amivantamab data for NSCLC subset, trying to bolster case for quick FDA approval

Having already filed for a quick OK for amivantamab in a subset of metastatic non-small cell lung cancer patients, J&J’s Janssen unit on Thursday presented more data at WCLC hoping to boost the experimental drug’s case.